Tag: DCGI
Zydus’s COVID-19 drug ‘Virafin’ gets DCGI nod
91.15% of patients treated with PegIFN were RT PCR negative by day 7. A single dose of the antiviral Virafin administered subcutaneously early on shows significant clinical and virological improvement in moderate COVID-19 adult patients.......................
Sputnik V vaccine authorized in India
India has become the 60th country to approve the Russian vaccine, Sputnik V, one of only three vaccines registered so far in the country.........................
Zydus Cadila vaccine candidate gets nod for Phase III clinical trials
The candidate has been supported by the National Biopharma Mission (NBM) under the aegis of BIRAC and the Department of Biotechnology, Government of India.......................
Wait over as DCGI approves Bharat Biotech & Serum Institute COVID-19...
After adequate examination, Central Drugs Standard Control Organisation decided to accept the recommendations of the Expert Committee, and accordingly, vaccines of Serum and Bharat Biotech are being approved for restricted use in an emergency situation
Enough compliances in place during COVID-19 vaccine development, assures regulator
Drugs Controller General of India has assured that the COVID-19 vaccines being developed and tested in India have followed all the right methodologies as per existing regulatory guidelines........................
Zydus seeks approval to commence Phase III clinical trials of its...
New Delhi: Zydus Cadila has announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D was found to be safe, well tolerated and immunogenic in...
Biological E begins clinical trials of its COVID-19 vaccine
The results of this clinical trial are expected to be available by February 2021..................
Are India’s pharma regulations denting patient safety?
Experts shed light on the cause of rising Vitamin C prices and why patients end up paying a higher price for basic affordable vitamins which were otherwise available at reasonable prices earlier......................
Jubilant launches JUBI-R, its generic version of COVID-19 drug remdesivir in...
Jubilant Generics, a subsidiary of Jubilant Life Sciences has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of INR 4,700 per vial of 100 mg (lyophilized injection)........................
DCGI nod to Serum Institute for conducting human trials of Oxford...
The Drugs Controller General of India has given the Serum Institute of India a green light to conduct phase 2 and 3 human trials of the Oxford-AstraZeneca COVID-19 vaccine candidate in India..................